This week's Fierce Pharma is brought to you by Clarivate.

WHITEPAPER

Leading Innovators in Gene Editing

The FDA’s recent approvals ofCasgevy and Lyfgenia marked a groundbreaking moment in gene editing therapeutics. As we step into this new era of medical innovation, what’s next for the field? Explore our latest resource to gain insights into:

• 🚀 Emerging startups uncovering novel targets and indications.
• ⚖️ Challenges in clinical trials, regulation, and IP protection for industry players.
• 🌍 The ripple effects on regulators, payers, clinicians, and patient outcomes.

Get an exclusive first look at the breakthroughs shaping the future of gene editing.